EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fractional picosecond laser treatment of non‐acne atrophic scars and scar erythema in Chinese patients

Jing Li iD, Fangfang Duan, Jie Kuang, Xiao Liu, Jing Pan, Jia Wei, Jinghui Zhao

Skin Research and Technology · 2024

DOI: 10.1111/srt.13856 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Skin Research and Technology, 2024. Verfasst von Jing Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, P.R. China. Hauptthemen laut MEDLINE: Cicatrix, Erythema. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fractional picosecond lasers (FPL) are reported to be effective and safe for atrophic acne scars and post‐acne erythema. However, there is no evidence regarding the effectiveness and safety of FPL treatment for non‐acne atrophic scars and scar erythema among Chinese patients.

Methods

In this retrospective study, 12 Chinese patients with non‐acne atrophic scars, including nine with scar erythema, were treated with one to three sessions of 1064 nm FPL treatment. Clinical improvement was objectively assessed through blinded evaluations by external physicians. A modified Manchester Scar Scale (mMSS) and the Clinician Erythema Assessment Scale (CEAS) were individually used to evaluate atrophic scars and scar erythema based on photographs. Physician‐assessed and subject‐assessed Global Aesthetic Improvement Scale (GAIS) were used to assess changes before and after FPL treatment. Patient satisfaction and adverse events were also documented.

Results

Total mMSS scores, as well as three parameters (color, distortion, and texture), were significantly decreased after FPL treatment, with a mean reduction of 3.18 ± 1.60 in total scores ( p < 0.05). The CEAS scores were significantly reduced from 2.41 ± 0.98 before treatment to 0.41 ± 0.40 at the final visit ( p < 0.05). Based on physician‐assessed and subject‐assessed GAIS scores, 11 (91.7%) patients were improved after FPL treatment. 33.3% of patients were very satisfied, and 41.7% were satisfied. No serious, prolonged (> 3 weeks) adverse events were observed.

Conclusion

Our study suggests that 1064 nm FPL treatment may be a promising option for non‐acne atrophic scars, especially with scar erythema. Further studies are needed to confirm our results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CicatrixErythemaAdultFemaleHumansMaleMiddle AgedYoung AdultAtrophyChinaEast Asian PeopleLaser TherapyLasers, Solid-StateLow-Level Light TherapyPatient SatisfactionRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

atrophic scarerythemafractional laserpicosecond laser

Autor:innen und Institutionen

  • Department of Dermatology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, P.R. China.
  • Fourth Medical College of Peking University, Beijing, P.R. China.
  • Clinical Epidemiology Research Center, Beijing Jishuitan Hospital, Capital Medical University, Beijing, P.R. China.

ORCID-Profile: Jing Li

Zitieren

APA

Li, J., Duan, F., Kuang, J., Liu, X., Pan, J., Wei, J., & Zhao, J. (2024). Fractional picosecond laser treatment of non‐acne atrophic scars and scar erythema in Chinese patients. Skin Research and Technology. https://doi.org/10.1111/srt.13856

Vancouver

Li J, Duan F, Kuang J, Liu X, Pan J, Wei J, et al. Fractional picosecond laser treatment of non‐acne atrophic scars and scar erythema in Chinese patients. Skin Research and Technology. 2024. doi:10.1111/srt.13856

BibTeX
@article{Li2024,
  author = {Li, Jing and Duan, Fangfang and Kuang, Jie and Liu, Xiao and Pan, Jing and Wei, Jia and Zhao, Jinghui},
  title = {Fractional picosecond laser treatment of non‐acne atrophic scars and scar erythema in Chinese patients},
  journal = {Skin Research and Technology},
  year = {2024},
  doi = {10.1111/srt.13856}
}
Kostenlos starten →